

Vemurafenib BRIM-3

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Serious and disabling adverse effects



Other adjustments



Upgrade for early stopping based on interim analysis of OS

Vemurafenib BRIM-3

SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Skin Cancers  
 Therapeutic Indication: As monotherapy for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma  
 Experimental Arm: Vemurafenib  
 Control Arm: Dacarbazine



